Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maravai Lifesciences Holdings (MRVI) Cash & Current Investments (2022 - 2025)

Maravai Lifesciences Holdings (MRVI) has 4 years of Cash & Current Investments data on record, last reported at $243.6 million in Q3 2025.

  • For Q3 2025, Cash & Current Investments fell 57.87% year-over-year to $243.6 million; the TTM value through Sep 2025 reached $243.6 million, down 57.87%, while the annual FY2024 figure was $323.8 million, 43.69% down from the prior year.
  • Cash & Current Investments reached $243.6 million in Q3 2025 per MRVI's latest filing, down from $269.9 million in the prior quarter.
  • Across five years, Cash & Current Investments topped out at $632.1 million in Q4 2022 and bottomed at $243.6 million in Q3 2025.
  • Average Cash & Current Investments over 4 years is $473.5 million, with a median of $575.0 million recorded in 2023.
  • Peak YoY movement for Cash & Current Investments: decreased 0.07% in 2024, then crashed 57.87% in 2025.
  • A 4-year view of Cash & Current Investments shows it stood at $632.1 million in 2022, then fell by 9.04% to $575.0 million in 2023, then tumbled by 43.69% to $323.8 million in 2024, then fell by 24.77% to $243.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Current Investments were $243.6 million in Q3 2025, $269.9 million in Q2 2025, and $285.1 million in Q1 2025.